Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials

医学 安慰剂 内科学 随机对照试验 临床试验 不利影响 病理 替代医学
作者
Jennifer A. Zimmer,Paul A. Ardayfio,Hong Wang,Rashna Khanna,Cynthia Duggan Evans,Ming Lu,JonDavid Sparks,Scott W. Andersen,Steve Lauzon,Emel Serap Monkul Nery,Chakib Battioui,Staci E. Engle,Alessandro Biffi,Diana Otero Svaldi,Stephen Salloway,Steven Mark Greenberg,Reisa Anne Sperling,Mark A. Mintun,Dawn A. Brooks,John Randall Sims
出处
期刊:JAMA Neurology [American Medical Association]
卷期号:82 (5): 461-461 被引量:206
标识
DOI:10.1001/jamaneurol.2025.0065
摘要

Importance: Amyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy. Identifying clinical features and individual risk factors for ARIA could facilitate effective prediction and prevention strategies. Objective: To characterize ARIA in participants treated with donanemab. Design, Setting, and Participants: These prespecified and post hoc exploratory analyses use data from the placebo-controlled portions of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials, conducted from December 2017 to December 2020 and from June 2020 to April 2023, respectively. Additional analyses are included from a stand-alone open-label addendum conducted from August 2021 through August 2023. Participants in the placebo-controlled trials and the open-label addendum aged 60 to 85 years with early symptomatic Alzheimer disease and elevated amyloid levels were included. The placebo-controlled trials, but not the addendum, had tau inclusion criteria. Interventions: Placebo-controlled trial participants were randomized 1:1 to receive placebo or donanemab, and all open-label participants received donanemab. Donanemab was administered every 4 weeks for up to 72 weeks. Main Outcomes and Measures: The primary outcomes were the frequency, radiographic severity, seriousness, symptoms, timing relative to donanemab treatment, and risk factors for ARIA. Results: Across 3030 total participants (placebo-controlled trials: 999 placebo participants, 984 donanemab participants; open-label addendum: 1047 donanemab participants), mean (SD) age was approximately 73.7 (6.0) years and 1684 participants (55.6%) were female. Frequencies of ARIA-edema/effusions (ARIA-E) and ARIA-microhemorrhages and hemosiderin deposition (ARIA-H) were higher with donanemab (24.4% and 31.3% in placebo-controlled trials, respectively; 19.8% and 27.2% in open-label addendum, respectively) than with placebo (1.9% and 13.0%, respectively). ARIA-E was mostly mild or moderate in severity. Serious ARIA-E was reported in 1.5% and symptomatic ARIA-E in 5.8% of donanemab-treated participants in the placebo-controlled trials. Symptoms most frequently reported with ARIA-E were headache and confusional state. In 58.3% of donanemab-treated participants with ARIA-E, the first event occurred by the third infusion (approximately month 3). Risk analysis demonstrated independent associations between ARIA-E and 6 baseline variables, including increased risk with APOE ε4 allele number, greater number of microhemorrhages, presence of cortical superficial siderosis, higher amyloid plaque, and elevated mean arterial pressure, and decreased risk with antihypertensive use. Conclusions and Relevance: ARIA is an adverse event associated with donanemab treatment that requires safety monitoring. Individual ARIA risk can be assessed by APOE ε4 status and baseline imaging findings. Trial Registrations: ClinicalTrials.gov Identifiers: NCT03367403 and NCT04437511.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Maestro_S的应助被冷酷的冰岚采纳,获得10
1秒前
xmn完成签到 ,获得积分10
1秒前
Ava的应助被王亚奇采纳,获得10
1秒前
默岩1990发布了新的文献求助10
2秒前
茜11122完成签到,获得积分10
3秒前
L_MING完成签到,获得积分10
3秒前
阿北完成签到,获得积分10
5秒前
5秒前
123完成签到,获得积分10
6秒前
新鲜楠瓜皮完成签到,获得积分10
7秒前
科研小白two完成签到 ,获得积分10
8秒前
坚强的小懒虫完成签到 ,获得积分10
9秒前
往徕完成签到,获得积分10
10秒前
10秒前
善良柜子完成签到 ,获得积分10
10秒前
土土完成签到,获得积分10
11秒前
11秒前
M83发布了新的文献求助10
12秒前
QwQ完成签到 ,获得积分10
13秒前
冰蓝色的忧伤完成签到,获得积分10
13秒前
王亚奇发布了新的文献求助10
14秒前
无趣完成签到,获得积分20
14秒前
Deiog完成签到 ,获得积分10
15秒前
黎黎原上草完成签到,获得积分10
16秒前
轻松大地完成签到,获得积分10
16秒前
搜集达人的应助被stoic采纳,获得10
16秒前
巧克力手印完成签到,获得积分10
17秒前
17秒前
18秒前
HYAn完成签到,获得积分10
18秒前
19秒前
灵巧的谷南完成签到 ,获得积分10
20秒前
dukui完成签到,获得积分10
20秒前
怕孤单的惜梦完成签到,获得积分10
22秒前
韭菜盒子发布了新的文献求助10
23秒前
茴香完成签到,获得积分10
23秒前
King强完成签到,获得积分10
23秒前
syvshc的应助被科研通管家采纳,获得10
24秒前
小二郎的应助被科研通管家采纳,获得10
25秒前
852的应助被科研通管家采纳,获得50
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185571
求助须知:如何正确求助?哪些是违规求助? 9574325
关于积分的说明 21835086
捐赠科研通 7783326
什么是DOI,文献DOI怎么找? 3434597
关于科研通互助平台的介绍 2558985
邀请新用户注册赠送积分活动 2481372